Ginisortamab

吉司妥单抗

Report date: 2025/07/29 20:00:11

Base Information

Drug NameGinisortamab
Drug Alias NameIMMUNOGLOBULIN G4 (232-PROLINE)ANTI-(HUMAN GREMLIN 1) (HUMAN MONOCLONAL UCB6114 .GAMMA.4-CHAIN)DISULFIDE WITH HUMAN MONOCLONAL UCB6114 .KAPPA.-CHAINDISULFIDE WITH HUMAN MONOCLONAL UCB6114 .KAPPAUCB-6114
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionGremlin-1 inhibitors
TargetsGremlin-1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUcb Biopharma Srl
China Registration ClassN/A

Develop Information

Active CompaniesUcb Biopharma SrlCancer Research UK
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A